191602-76-3

Usage

Uses

Used in Organic Synthesis:
5-(3-BROMO-4-METHOXY-PHENYL)-2H-TETRAZOLE is utilized as a key intermediate in organic synthesis for the creation of complex organic molecules. Its unique structure allows for versatile reactions, making it a valuable component in the synthesis of various compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5-(3-BROMO-4-METHOXY-PHENYL)-2H-TETRAZOLE is used as a building block for the development of potential drug candidates. Its presence in molecular structures can contribute to the desired biological activities of these candidates.
Used in Antimicrobial Applications:
5-(3-BROMO-4-METHOXY-PHENYL)-2H-TETRAZOLE has been studied for its antimicrobial properties, making it a candidate for use in applications aimed at combating microbial infections.
Used in Antiviral Applications:
5-(3-BROMO-4-METHOXY-PHENYL)-2H-TETRAZOLE has also been explored for its potential antiviral activities, suggesting its use in the development of antiviral medications or treatments.
Used in Anti-inflammatory Applications:
5-(3-BROMO-4-METHOXY-PHENYL)-2H-TETRAZOLE's anti-inflammatory potential has been of interest, indicating its possible use in the treatment of inflammatory conditions.
Used in Material Science:
In the field of material science, 5-(3-BROMO-4-METHOXY-PHENYL)-2H-TETRAZOLE is considered for its potential use in developing new materials or enhancing existing ones, thanks to its unique chemical and physical properties.
Used in Product Improvement:
5-(3-BROMO-4-METHOXY-PHENYL)-2H-TETRAZOLE is also explored for its role in improving the performance or characteristics of existing products, potentially across various industries, by incorporating its properties into their formulations.

Upstream product

• 117572-79-9 3-bromo-4-methoxybenzonitrile 

Relevant academic research and scientific papers

Practical scale up synthesis of carboxylic acids and their bioisosteres 5-substituted-1H-tetrazoles catalyzed by a graphene oxide-based solid acid carbocatalyst

Herein, catalytic application of a metal-free sulfonic acid functionalized reduced graphene oxide (SA-rGO) material is reported for the synthesis of both carboxylic acids and their bioisosteres, 5-substituted-1H-tetrazoles. SA-rGO as a catalytic material incorporates the intriguing properties of graphene oxide material with additional benefits of highly acidic sites due to sulfonic acid groups. The oxidation of aldehydes to carboxylic acids could be efficiently achieved using H2O2as a green oxidant with high TOF values (9.06-9.89 h?1). The 5-substituted-1H-tetrazoles could also be effectively synthesized with high TOF values (12.08-16.96 h?1). The synthesis of 5-substituted-1H-tetrazoles was corroborated by single crystal X-ray analysis and computational calculations of the proposed reaction mechanism which correlated well with experimental findings. Both of the reactions could be performed efficiently at gram scale (10 g) using the SA-rGO catalyst. SA-rGO displays eminent reusability up to eight runs without significant decrease in its productivity. Thus, these features make SA-rGO riveting from an industrial perspective.

A comparative study between heterogeneous stannous chloride loaded silica nanoparticles and a homogeneous stannous chloride catalyst in the synthesis of 5-substituted 1: H -tetrazole

Heterogeneous SnCl2-nano-SiO2 efficiently catalyzed 5-substituted 1H-tetrazole synthesis with excellent yield. The catalyst was characterized by using FT-IR, TGA, TEM, and EDX. It is widely applicable on aliphatic, aromatic, heteroaromatic and sterically hindered nitriles with five time recyclability. Being simple and an economically viable approach for the synthesis of SnCl2-nano-SiO2 are additional advantages.

An efficient and economical synthesis of 5-substituted 1 H -tetrazoles via Pb(II) salt catalyzed [3+2] cycloaddition of nitriles and sodium azide

A simple, mild and efficient method is developed for the synthesis of 5-substituted 1H-tetrazoles. Out of three used Pb(II) catalysts, lead chloride (PbCl2) has been found to be an efficient catalyst for [3+2] cycloaddition of NaN3 with aromatic and aliphatic nitriles to afford 5-substituted 1H-tetrazoles. The catalyst is reusable up to four cycles with consistent activity. The cost effectiveness and easy availability of the catalyst, simple methodology, excellent yield and easy work-up are the additional advantages.

Synthetic application of gold nanoparticles and auric chloride for the synthesis of 5-substituted 1H-tetrazoles

An effective one-pot, convenient gold catalyzed synthesis of 5-substituted 1H-tetrazoles has been discussed. The study demonstrated the comparative overview for utilization of gold(iii) and gold nano-particles (spheres) as a catalyst. Detailed understandi

(NH4)2Ce(NO3)6 as an inexpensive, eco-friendly, efficient catalyst for the synthesis of 5-substituted 1-H tetrazoles from nitriles

Ceric ammonium nitrate (CAN) is found to be a suitable, inexpensive, and effective non-toxic catalyst for a smooth (3+2) cycloaddition of organic nitriles with NaN3 to afford 5-substituted 1H-tetrazoles in excellent yields. Shorter reaction times, easy work-up, and substantial and pure product formation are the key advantages of the present method.

Efficient heterogeneous silver nanoparticles catalyzed one-pot synthesis of 5-substituted 1H-tetrazoles

Silver nanoparticles (AgNPs), characterized by TEM, EDX and UV studies were used as an efficient heterogeneous catalyst for the synthesis of 5-substituted 1H-tetrazoles from various nitriles possessing different functional groups in excellent yields. All

AgNO3 catalyzed synthesis of 5-substituted-1H-tetrazole via [3+2] cycloaddition of nitriles and sodium azide Dedicated to the memory of late Dr. Tarkeshwar Gupta

An efficient one-pot, convenient catalysis for the synthesis of 5-substituted-1H-tetrazoles is reported. The [3+2] cycloaddition involves various nitriles, sodium azide in refluxing DMF and AgNO3 as catalyst to give corresponding 5-substituted-

CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS

This invention provides compounds defined by Formula I Z-L-R1-Q-D-(V1)m-R2 I or a pharmaceutically acceptable salt thereof, wherein Z, L, R1, Q, D, V1, m, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS

This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein Rl, Q, S, T, U, V, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a' pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a' compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency,,inflammatory bowel, disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically, acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active, component as described in the specification.